CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Fourth Trimester Mobile ToolWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (5)

Name (Synonyms) Correlation
drug1340 Liberase Enzyme (Roche) Wiki 1.00
drug1160 IV Deployment Of cSVF In Sterile Normal Saline IV Solution Wiki 1.00
drug1487 Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF) Wiki 1.00
drug2361 Sterile Normal Saline for Intravenous Use Wiki 1.00
drug537 Centricyte 1000 Wiki 1.00

Correlated MeSH Terms (10)

Name (Synonyms) Correlation
D011649 Pulmonary Alveolar Proteinosis NIH 1.00
D054990 Idiopathic Pulmonary Fibrosis NIH 1.00
D011658 Pulmonary Fibrosis NIH 0.45
D017563 Lung Diseases, Interstitial NIH 0.32
D008171 Lung Diseases, NIH 0.26
D011024 Pneumonia, Viral NIH 0.13
D003141 Communicable Diseases NIH 0.09
D007239 Infection NIH 0.06
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (4)

Name (Synonyms) Correlation
HP:0006517 Intraalveolar phospholipid accumulation HPO 1.00
HP:0002206 Pulmonary fibrosis HPO 0.45
HP:0006515 Interstitial pneumonitis HPO 0.32
HP:0002088 Abnormal lung morphology HPO 0.26

There is one clinical trial.

Clinical Trials

1 Fourth Trimester - A Web-based Tool for Postpartum Care to Address the Needs of Underserved Women

The postpartum period is a critical time for both maternal and child health, and more than half of all maternal deaths occur postpartum, from one day to one year after birth. This poor outcome is linked to the racial and ethnic disparities that disproportionately effects low income and black women. To reduce the burden of the postpartum period for this population, the goal of this project is to develop an accessible, targeted online tool designed to address the needs of underserved women who are at greater risk for adverse postpartum outcomes by providing the appropriate tools, knowledge and skills to improve postpartum health.

NCT04475718 Pregnancy Related Postpartum Sadness Behavioral: Fourth Trimester Mobile Tool

Primary Outcomes

Description: Measured by the Connor-Davidson Resilience Scale, a 25-item scale covering 17 domains related to resiliency, used with a variety of populations, across a wide range of languages, racial/ethnic, and cultural groups. It has strong psychometric properties and validated short forms. Scoring of the scale is based on summing the total of all items, each of which is scored from 0-4. For the CD-RISC-25, the full range is from 0 to 100, with higher scores reflecting greater resilience.

Measure: Change from Baseline Resilience at 4 Weeks

Time: baseline, 4 weeks

Secondary Outcomes

Description: The Edinburgh Postnatal Depression Scale (EPDS) will be used to assess depressive symptoms. The 10-question Edinburgh Postnatal Depression Scale (EPDS) is a valuable and efficient way of identifying patients at risk for perinatal depression. Scores range from 0-30. Higher scores indicate more depressive symptoms. Mothers who score above 13 are likely to be suffering from a depressive illness of varying severity.

Measure: Change from Baseline Depressive Symptoms at 4 Weeks Using the Edinburgh Postnatal Depression Scale (EPDS)

Time: baseline, 4 weeks

Description: The Center for Epi Studies of Depression (CES-D) will be used to assess depressive symptoms. The CES-D has been used extensively in culturally diverse populations. The CES-D is a 20-item measure that asks caregivers to rate how often over the past week they experienced symptoms associated with depression, such as restless sleep, poor appetite, and feeling lonely. Scores range from 0 to 60, with high scores indicating greater depressive symptoms.

Measure: Change from Baseline Depressive Symptoms at 4 Weeks Using the Center for Epi Studies of Depression (CES-D)

Time: baseline, 4 weeks

Description: The Patient Health Question (PHQ-9) will be used to identify major depression. Scores range from 1-27, with higher scores indicating greater severity of depression.

Measure: Change from Baseline Depressive Symptoms at 4 Weeks Using the Patient Health Question (PHQ-9)

Time: baseline, 4 weeks

Description: The State-Trait Anxiety Inventory (STAI) is a measure of trait and state anxiety with 20 items for assessing trait anxiety and 20 for state anxiety. It has been validated for use with pregnant women. All items are rated on a 4-point scale (e.g., from "Almost Never" to "Almost Always"). The range of possible scores for form Y of the STAI varies from a minimum score of 20 to a maximum score of 80 on both the STAI-T and STAI-S subscales. Higher scores indicate greater anxiety.

Measure: Change from Baseline Parent Anxiety at 4 Weeks

Time: baseline, 4 weeks

Description: The Behavioral Risk Factor Surveillance System (BRFSS) Historical Questions will be used to address topics including health insurance coverage, continuity, cost barriers, health care visits, and satisfaction with care. Specific questions of interest relevant to this population will be selected by the investigators. Change in individual question responses will be assessed from baseline to 4 weeks.

Measure: Change from Baseline Health Care Access and Utilization at 4 Weeks

Time: baseline, 4 weeks

Description: Emerging scales on COVID-19 include The Fear of COVID-19 Scale and the Coronavirus Anxiety Scale. Where no validated scales exist, questions will be developed specific to the COVID-19 crisis for this population. Existing scales will be used to inform the development of a study-specific instrument to assess COVID-19 specific fear and anxiety in postpartum women. Specific questions of interest relevant to this population will be selected by the investigators. Change in individual question responses will be assessed from baseline to 4 weeks.

Measure: Change from COVID-19 Specific Fear and Anxiety at 4 Weeks

Time: baseline, 4 weeks

No related HPO nodes (Using clinical trials)